NASDAQ:GRDX

Entero Therapeutics (GRDX) Stock Price, News & Analysis

$3.29 -0.16 (-4.72%)
As of 03:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Entero Therapeutics Stock (NASDAQ:GRDX)

Advanced

Key Stats

Today's Range
$3.12
▼
$3.56
50-Day Range
$2.86
▼
$5.84
52-Week Range
$1.87
▼
$6.93
Volume
102,450 shs
Average Volume
118,846 shs
Market Capitalization
$28.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Entero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency.

Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency. These are investigational products and are not approved treatments.

The company was formerly known as First Wave BioPharma before adopting the Entero Therapeutics name. Its work has centered on developing drug candidates rather than marketing approved medicines.

AI Generated. May Contain Errors.

Entero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
21st Percentile Overall Score

GRDX MarketRank™: 
1.03370324702 of 5 stars

Entero Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 482nd out of 574 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Entero Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entero Therapeutics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entero Therapeutics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Entero Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.43% of the float of Entero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entero Therapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entero Therapeutics has recently decreased by 69.28%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Entero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Entero Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Entero Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Entero Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Entero Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entero Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.75% of the stock of Entero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    12.30% of the stock of Entero Therapeutics is held by institutions.

  • Read more about Entero Therapeutics' insider trading history.
Receive GRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GRDX Stock News Headlines

See More Headlines

GRDX Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $2.91 on February 6, 2026. Since then, GRDX shares have increased by 12.4% and is now trading at $3.2710.

Entero Therapeutics, Inc. (NASDAQ:GRDX) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.27) EPS for the quarter. The business had revenue of $38.11 thousand for the quarter. Entero Therapeutics had a negative net margin of 11,237.77% and a negative trailing twelve-month return on equity of 65.36%.

Shares of GRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Software
Sub-Industry
Application Software
Current Symbol
NASDAQ:GRDX
CIK
1604191
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.39 million
Net Margins
-11,237.77%
Pretax Margin
-12,368.66%
Return on Equity
-65.36%
Return on Assets
-30.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.26
Quick Ratio
0.16

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
698.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
1.82

Miscellaneous

Outstanding Shares
8,540,000
Free Float
7,078,000
Market Cap
$27.93 million
Optionable
N/A
Beta
1.67
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:GRDX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners